Harvard Apparatus Regenerative Technology (HRGN) Q4 2024 earnings summary

Executive summary

• Clinical-stage biotech focused on regenerative medicine for GI tract and airway disorders, leveraging proprietary cell-therapy platforms using autologous stem cells for organ regeneration.

• Lead product is the Cellspan Esophageal Implant, with FDA-approved phase 1 trial for esophageal reconstruction; patient recruitment delays persist due to stringent criteria and logistical challenges.

• Consumer Health Products segment launched in 2023, selling dietary supplements in Asia via eCommerce; exclusive global distribution agreement signed in October 2024.

• Company has not achieved regulatory approval for any clinical products and continues to incur significant operating losses.

Financial highlights

• Product revenue grew to $430,000 in 2024 from $103,000 in 2023, driven by expanded distribution of consumer health products in Asia.

• Net loss for 2024 was $7.7 million, an improvement from $8.9 million in 2023.

• Operating expenses decreased 10% year-over-year to $8.2 million, with R&D down 25% to $2.3 million and G&A down 12% to $5.0 million.

• Accumulated deficit reached $99.7 million as of December 31, 2024.

• Cash and cash equivalents were $2.5 million at year-end, expected to fund operations into Q2 2025.

Outlook and guidance

• Additional capital is required by Q2 2025 to continue operations; failure to secure funding may force curtailment or cessation of business.

• Company plans to expand clinical trials internationally and pursue regulatory approvals in the U.S., China, Europe, and the U.K.

• Focus remains on advancing the esophageal implant through clinical development and commercialization, with potential expansion to other organs.